Restoring and maintaining sinus rhythm versus rate control treatment strategy to reduce cardiovascular mortality in patients with atrial fibrillation and congestive heart failure: a randomised controlled trial

Montreal Heart Institute (Canada)0 个研究点目标入组 1,375 人开始时间: 2005年9月26日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Symptomatic CHF (New York Heart Association [NYHA] class II - IV) at some time during the 6 months before randomisation (instead of '3 months')
•2. Aged greater than or equal to 50 years old, either sex
•3. Left ventricular ejection fraction less than or equal to 35%
•4. History of significant atrial fibrillation
•5. Patients must be eligible for long term treatment with either treatment strategy of AF
•6. AF is known to be present and uninterrupted for greater than 12 months prior to randomisation

•1. Reverse cause of AF such as acute pericarditis, pulmonary embolism, hyperthyroidism, alcohol intoxication
•2. Unstable (pulmonary oedema, hypoperfusion) decompensated CHF
•3. Antiarrhythmic drugs other than calcium channel blockers, beta-blockers or digoxin required for other arrhythmias or indications
•4. Atrial fibrillation occurring and not persisting beyond 10 days after surgery or myocardial infarction
•5. Second or third degree AV block, sinus pause greater than 3 seconds, resting heart rate less than 50 bpm without a permanent pacemaker
•6. History of drug-induced or congenital long QT syndrome
•7. Reversible causes of CHF such as severe aortic or mitral stenosis and tachycardia-induced cardiomyopathy
•8. Prior AV nodal ablation or maze surgery
•9. Probable cardiac transplantation in the next 6 months
•10. Chronic renal failure requiring dialysis
•11. Women of childbearing potential and not on a reliable method of birth control

发起方

Montreal Heart Institute (Canada)